Ushbu ishga iqtibos qilgan ishlar

3 ta ish

Ish: Long-term outcomes following CAR T cell therapy: what we know so far

1. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   MaqolaCAR-T cell therapy researchJournal of Hematology & Oncology20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000083

2. Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy

   Qianqian Huang, Fan Tong, Jiantao Chen +5

   Sharh maqolaNanoplatforms for cancer theranosticsAdvanced Science20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.review-article.000021

3. Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy

   Mutaz Jamal Al-khreisat, Waleed K. Abdulsahib, Ihsan Khudhair Jasim +6

   MaqolaCancer Immunotherapy and BiomarkersAnnals of Hematology20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.009488